Glycemic variability in inadequately controlled type 1 diabetes and type 2 diabetes on intensive insulin therapy: a cross-sectional, observational study.

BACKGROUND Glycemic variability is suggested to be a predictor for the risk of complications of diabetes. A multitude of parameters to express glycemic variability have been described, but no gold standard exists. The easy measurable parameter SD has been shown to be strongly related to other parameters in a group of patients with mostly well-controlled type 1 and type 2 diabetes mellitus (T1DM and T2DM, respectively). Glycemic variability is higher in T1DM compared with T2DM in mixed populations with different treatments, but studies in patients on intensive insulin treatment are lacking. Therefore in this study we investigate different parameters of glycemic variability and differences between T1DM and T2DM in inadequately controlled patients on intensive insulin treatment. METHODS In this cross-sectional, observational study we describe glycemic variability, measured as SD, coefficient of variation, continuous overall net glycemic action, and mean of daily differences in a cohort of inadequately controlled T1DM (n = 166) and T2DM (n = 58) patients on intensive insulin treatment. RESULTS SD of 48 h (SD(total)) was highly correlated to all other measured parameters of glycemic variability (r = 0.66-0.88). All parameters of glycemic variability were significantly higher in T1DM compared to T2DM (P < 0.001), although hemoglobin A1c and mean glucose were comparable and treatment regimen was the same. In the cohort of T2DM patients but not T1DM, a longer duration of insulin therapy was associated with higher glycemic variability. CONCLUSIONS SD(total) is a conveniently measurable parameter to express glycemic variability in patients with inadequate control with intensive insulin therapy. Patients with T1DM and long-lasting T2DM have the highest glycemic variability.

[1]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[2]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[3]  W. Duckworth,et al.  Sources of glucose variability in insulin‐treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES) , 2004, Clinical endocrinology.

[4]  C. McDonnell,et al.  A novel approach to continuous glucose analysis utilizing glycemic variation. , 2005, Diabetes technology & therapeutics.

[5]  Bruce W Bode,et al.  Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. , 2005, Diabetes care.

[6]  Michael Brownlee,et al.  Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. , 2006, JAMA.

[7]  J. DeVries,et al.  Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes , 2007, Diabetologia.

[8]  R. Hovorka,et al.  Glycemic Variability Correlates Strongly With Postprandialβ-Cell Dysfunction in a Segment of Type 2 Diabetic Patients Using Oral Hypoglycemic Agents , 2009, Diabetes Care.

[9]  D. Owens,et al.  Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy , 2009, Diabetologia.

[10]  David Rodbard,et al.  Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. , 2009, Diabetes technology & therapeutics.

[11]  Boris Kovatchev,et al.  Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. , 2009, Diabetes technology & therapeutics.

[12]  David Rodbard,et al.  New and improved methods to characterize glycemic variability using continuous glucose monitoring. , 2009, Diabetes technology & therapeutics.

[13]  G. Paolisso,et al.  Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. , 2010, Journal of diabetes and its complications.

[14]  Frits Holleman,et al.  Glucose variability; does it matter? , 2010, Endocrine reviews.